

Studies on these drugs indicate that their efficacy is similar to that of the more traditional NSAIDs.

However, they are associated with a decreased risk of gastrointestinal effects.

Thus far, COX-2 inhibitors have largely been used as second-line drugs for management of pain in patients who cannot tolerate other NSAIDs, but they will probably become first-line treatment in the future.